Elicio Therapeutics, Inc. (ELTX)

Market Cap	93.01M
Revenue (ttm)	n/a
Net Income (ttm)	-35.20M
Shares Out	10.22M
EPS (ttm)	-6.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,882
Open	9.29
Previous Close	9.25
Day's Range	9.00 - 9.20
52-Week Range	2.96 - 24.39
Beta	n/a
Analysts	Buy
Price Target	11.00 (+20.88%)
Earnings Date	May 15, 2024

About ELTX

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: ELTX

Analyst Forecast

According to 2 analysts, the average rating for ELTX stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 20.88% from the latest price.

Price Target

$11.0

(20.88% upside)

Analyst Consensus: Buy